vs
Side-by-side financial comparison of Monopar Therapeutics (MNPR) and RESEARCH FRONTIERS INC (REFR). Click either name above to swap in a different company.
Monopar Therapeutics is the larger business by last-quarter revenue ($73.5K vs $72.1K, roughly 1.0× RESEARCH FRONTIERS INC). RESEARCH FRONTIERS INC runs the higher net margin — -1061.5% vs -2334.5%, a 1273.1% gap on every dollar of revenue. On growth, Monopar Therapeutics posted the faster year-over-year revenue change (-42.7% vs -59.5%). Over the past eight quarters, Monopar Therapeutics's revenue compounded faster (208.9% CAGR vs -52.0%).
Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative targeted therapies for cancer patients. Its lead product candidates address unmet oncology medical needs, serving North American markets and partnering with global healthcare and research institutions to advance its development pipeline.
Research Frontiers is an American nanotechnology company based in Woodbury, New York that was founded by Robert Saxe in 1965 to develop light control technology from Polaroid known as smart glass. The company develops and licenses its patented SPD-SmartGlass technology. The company currently has six full-time employees.
MNPR vs REFR — Head-to-Head
Income Statement — Q2 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $73.5K | $72.1K |
| Net Profit | $-1.7M | $-765.6K |
| Gross Margin | — | — |
| Operating Margin | -2434.5% | -1072.5% |
| Net Margin | -2334.5% | -1061.5% |
| Revenue YoY | -42.7% | -59.5% |
| Net Profit YoY | 22.0% | -25.9% |
| EPS (diluted) | — | $-0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $72.1K | ||
| Q3 25 | — | $359.4K | ||
| Q2 25 | — | $129.9K | ||
| Q1 25 | — | $559.8K | ||
| Q4 24 | — | $178.2K | ||
| Q3 24 | — | $354.4K | ||
| Q2 24 | $73.5K | $489.6K | ||
| Q1 24 | $82.2K | $313.4K |
| Q4 25 | — | $-765.6K | ||
| Q3 25 | — | $-298.5K | ||
| Q2 25 | — | $-803.8K | ||
| Q1 25 | — | $-177.7K | ||
| Q4 24 | — | $-607.9K | ||
| Q3 24 | — | $-166.8K | ||
| Q2 24 | $-1.7M | $-94.0K | ||
| Q1 24 | $-1.6M | $-442.6K |
| Q4 25 | — | -1072.5% | ||
| Q3 25 | — | -84.6% | ||
| Q2 25 | — | -627.5% | ||
| Q1 25 | — | -42.8% | ||
| Q4 24 | — | -350.4% | ||
| Q3 24 | — | -65.4% | ||
| Q2 24 | -2434.5% | -23.7% | ||
| Q1 24 | -2097.5% | -149.9% |
| Q4 25 | — | -1061.5% | ||
| Q3 25 | — | -83.0% | ||
| Q2 25 | — | -618.8% | ||
| Q1 25 | — | -31.7% | ||
| Q4 24 | — | -341.2% | ||
| Q3 24 | — | -47.1% | ||
| Q2 24 | -2334.5% | -19.2% | ||
| Q1 24 | -1997.5% | -141.2% |
| Q4 25 | — | $-0.02 | ||
| Q3 25 | — | $-0.01 | ||
| Q2 25 | — | $-0.02 | ||
| Q1 25 | — | $-0.01 | ||
| Q4 24 | — | $-0.03 | ||
| Q3 24 | — | $0.00 | ||
| Q2 24 | — | $0.00 | ||
| Q1 24 | — | $-0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $6.1M | $664.3K |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $6.1M | $933.6K |
| Total Assets | $7.2M | $2.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $664.3K | ||
| Q3 25 | — | $1.1M | ||
| Q2 25 | — | $1.3M | ||
| Q1 25 | — | $1.4M | ||
| Q4 24 | — | $2.0M | ||
| Q3 24 | — | $1.6M | ||
| Q2 24 | $6.1M | $1.9M | ||
| Q1 24 | $7.8M | $2.1M |
| Q4 25 | — | $933.6K | ||
| Q3 25 | — | $1.5M | ||
| Q2 25 | — | $1.8M | ||
| Q1 25 | — | $2.4M | ||
| Q4 24 | — | $2.6M | ||
| Q3 24 | — | $2.8M | ||
| Q2 24 | $6.1M | $3.0M | ||
| Q1 24 | $7.5M | $3.1M |
| Q4 25 | — | $2.3M | ||
| Q3 25 | — | $2.8M | ||
| Q2 25 | — | $3.2M | ||
| Q1 25 | — | $3.8M | ||
| Q4 24 | — | $4.0M | ||
| Q3 24 | — | $3.0M | ||
| Q2 24 | $7.2M | $3.4M | ||
| Q1 24 | $8.9M | $3.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $-465.9K |
| Free Cash FlowOCF − Capex | — | $-466.1K |
| FCF MarginFCF / Revenue | — | -646.2% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-1.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-465.9K | ||
| Q3 25 | — | $-143.5K | ||
| Q2 25 | — | $-78.4K | ||
| Q1 25 | — | $-641.3K | ||
| Q4 24 | — | $47.1K | ||
| Q3 24 | — | $-257.9K | ||
| Q2 24 | $-1.7M | $-186.9K | ||
| Q1 24 | $-1.7M | $-391.1K |
| Q4 25 | — | $-466.1K | ||
| Q3 25 | — | $-143.9K | ||
| Q2 25 | — | $-78.5K | ||
| Q1 25 | — | $-641.4K | ||
| Q4 24 | — | $46.2K | ||
| Q3 24 | — | $-258.5K | ||
| Q2 24 | — | $-187.0K | ||
| Q1 24 | — | $-391.2K |
| Q4 25 | — | -646.2% | ||
| Q3 25 | — | -40.0% | ||
| Q2 25 | — | -60.5% | ||
| Q1 25 | — | -114.6% | ||
| Q4 24 | — | 25.9% | ||
| Q3 24 | — | -72.9% | ||
| Q2 24 | — | -38.2% | ||
| Q1 24 | — | -124.8% |
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | — | 0.2% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
